Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the appointment of Chinmay Sharma, Executive Vice President - ...

London: GSK plc has announced the New Drug Application (NDA) for linerixibat, an investigational targeted inhibitor of the ...

Take a closer look at London's biotech hub – renowned for its thriving life sciences ecosystem and world-class infrastructure ...

(Alliance News) - GSK PLC on Monday announced the US Food & Drug Administration has accepted for review the new drug application for its liver disease treatment, linerixibat.

Drugmaker GSK revealed on Monday that a new drug application for its linerixibat asset had been accepted for review by the US ...

(Alliance News) - GSK PLC on Friday said its drug Blenrep has received a "positive opinion" from the European Medicines Agency's Committee for Medicinal Products for Human Use.

There’s already overlap in the pharmaceutical industry between the U.K. and Pennsylvania, but details in Trump’s trade deal ...

Stephen Hemsley returned to the top job last month after the healthcare giant reported its first earnings miss since 2008.

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

London-based GSK paid iTeos $625 million upfront for rights to belrestotug four years ago. At the time, interest in TIGIT was riding high as Bristol Myers Squibb, Gilead Sciences, Merck & Co. and ...

This week saw two major life sciences investments in London, as GSK unveiled plans to move its headquarters to a central location in the city, while an ambitious plan to develop a new biosciences ...

GSK agreed to buy an experimental medicine from a Cambridge biotech for as much as $2 billion to shore up its drug pipeline and muscle into the promising field of liver therapies. The treatment ...